TB Online is no longer maintained. This is an archive of the site. For news on TB please go to: https://globaltbcab.org/

China approves Sirturo for MDR-TB

Xian Janssen Pharmaceutical Ltd. announced that the China Food and Drug Administration (CFDA) has approved SIRTURO® (bedaquiline) for use as part of combination therapy in adult patients (18 years and older) with pulmonary multidrug-resistant TB (MDR-TB).

To read the full announcement, click here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:


News

By Xian Janssen Pharmaceutical Ltd.

Published: Dec. 24, 2016, 4 p.m.

Last updated: Dec. 24, 2016, 5:04 p.m.

Print Share